Overview

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with gemcitabine. The study is sponsored by AstraZeneca.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Gemcitabine